BACKGROUND: Cystatin C, which has long been regarded as a biomarker that indicates kidney functions, has recently been recognized as an inflammatory marker in the human body. AIM: To elucidate how cystatin C is related to the prognosis of systolic heart failure patients. METHODS: Patients with systolic heart failure who were admitted to the fourth affiliated hospital of Harbin Medical University between January and April 2008 were enrolled in this study. Serum homocysteine, high-sensitivity C-reactive protein (hs-CRP) and cystatin C levels were determined and all the patients received an average of 2 years of follow-up for occurrence of death, heart transplantation or readmission with worsening heart failure. RESULTS: Of 138 patients enrolled, those who experienced adverse outcomes (e.g. cardiac death, heart transplantation or progressive heart failure) (n = 21) had considerably higher mean levels of serum homocysteine (28.6 ± 13.4 vs 14.4 ± 6.3mg/L; P < 0.01), hs-CRP (17.5 ± 14.1 vs 6.4 ± 7.7 μmol/L; p < 0.01) and cystatin C (1.63 ± 0.81 vs 0.91 ± 0.27 mg/L; P < 0.01) than those without adverse outcomes (n = 117). Furthermore, the Cox proportional hazards model demonstrated that serum homocysteine, hs-CRP and cystatin C are all independent predictors of adverse outcomes. CONCLUSIONS: Cystatin C, together with hs-CRP and homocysteine, is an independent risk factor that is important in the prognosis of patients with systolic heart failure.
BACKGROUND:Cystatin C, which has long been regarded as a biomarker that indicates kidney functions, has recently been recognized as an inflammatory marker in the human body. AIM: To elucidate how cystatin C is related to the prognosis of systolic heart failurepatients. METHODS:Patients with systolic heart failure who were admitted to the fourth affiliated hospital of Harbin Medical University between January and April 2008 were enrolled in this study. Serum homocysteine, high-sensitivity C-reactive protein (hs-CRP) and cystatin C levels were determined and all the patients received an average of 2 years of follow-up for occurrence of death, heart transplantation or readmission with worsening heart failure. RESULTS: Of 138 patients enrolled, those who experienced adverse outcomes (e.g. cardiac death, heart transplantation or progressive heart failure) (n = 21) had considerably higher mean levels of serum homocysteine (28.6 ± 13.4 vs 14.4 ± 6.3mg/L; P < 0.01), hs-CRP (17.5 ± 14.1 vs 6.4 ± 7.7 μmol/L; p < 0.01) and cystatin C (1.63 ± 0.81 vs 0.91 ± 0.27 mg/L; P < 0.01) than those without adverse outcomes (n = 117). Furthermore, the Cox proportional hazards model demonstrated that serum homocysteine, hs-CRP and cystatin C are all independent predictors of adverse outcomes. CONCLUSIONS:Cystatin C, together with hs-CRP and homocysteine, is an independent risk factor that is important in the prognosis of patients with systolic heart failure.
Authors: Quynh A Truong; Jackie Szymonifka; James L Januzzi; Jigar H Contractor; Roderick C Deaño; Neal A Chatterjee; Jagmeet P Singh Journal: Heart Rhythm Date: 2018-12-24 Impact factor: 6.343
Authors: Agata Bielecka-Dabrowa; Anna Gluba-Brzózka; Marta Michalska-Kasiczak; Małgorzata Misztal; Jacek Rysz; Maciej Banach Journal: Int J Mol Sci Date: 2015-05-12 Impact factor: 5.923
Authors: Elisabet Zamora; Josep Lupón; Marta de Antonio; Joan Vila; Amparo Galán; Paloma Gastelurrutia; Agustín Urrutia; Antoni Bayes-Genis Journal: PLoS One Date: 2012-12-11 Impact factor: 3.240